58960-71-7

Basic information

• Product Name: BOC-TYR(3,5-BR2)-OH
• Synonyms: BOC-3,5-DIBROMO-L-TYROSINE;BOC-3,5-DIBROMO-TYR-OH;BOC-3,5-DIBROMO-TYROSINE;BOC-TYR(3,5-BR2)-OH;BOC-PHE(3,5-BR 2, 4-OH)-OH;N-ALPHA-T-BUTOXYCARBONYL-L-(3,5-DIBROMO, 4-HYDROXY)PHENYLALANINE;N-ALPHA-T-BUTOXYCARBONYL-L-(3,5-DIBROMO)TYROSINE;Boc-3,5-dibromo-L-Tyr-OH
• CAS NO: 58960-71-7
• Molecular Formula: C₁₄H₁₇Br₂NO₅
• Molecular Weight: 439.1
• Mol File: 58960-71-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 516.118 °C at 760 mmHg
• Flash Point: 265.939 °C
• Appearance: /
• Density: 1.692 g/cm³
• Refractive Index: 1.591
• Storage Temp.: Store at RT.
• CAS DataBase Reference: BOC-TYR(3,5-BR2)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-TYR(3,5-BR2)-OH(58960-71-7)
• EPA Substance Registry System: BOC-TYR(3,5-BR2)-OH(58960-71-7)

Safety Data

• Hazardous Substances Data: 58960-71-7(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

InChI:InChI=1/C14H17Br2NO5/c1-14(2,3)22-13(21)17-10(12(19)20)6-7-4-8(15)11(18)9(16)5-7/h4-5,10,18H,6H2,1-3H3,(H,17,21)(H,19,20)/t10-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 76912-56-6 L-3-(3',4',5'-tribromophenyl)alanine 
• 300-38-9 3,5-dibromo-L-tyrosine 
• 60-18-4 L-tyrosine 
• 943-80-6 4-amino-L-phenylalanine 
• 76912-54-4 L-3-(4'-amino-3',5'-dibromophenyl)alanine 

Downstream Products

• 85676-29-5 Boc-Tyr(3,5-diBr)-Arg-OMe_.0.5HCl 
• 173383-06-7 (S)-[(S)-2-Amino-3-(3,5-dibromo-4-hydroxy-phenyl)-propionylamino]-(3,5-dimethoxy-phenyl)-acetic acid methyl ester 
• 864738-89-6 N²-[N-(1,1-dimethylethoxycarbonyl)-3,5-dibromo-L-tyrosyl]-N⁶-(phenylmethoxycarbonyl)-D-lysine-2-phenethylamide 
• 864738-91-0 N²-[N-(1,1-dimethylethoxycarbonyl)-3,5-dibromo-L-tyrosyl]-N⁶-(phenylmethoxycarbonyl)-L-lysine-2-phenethylamide 
• 768360-55-0 Boc-(3,5-dibromo-Tyr)-Ser-Leu-OMe 
• 768360-59-4 (3,5-dibromo-Tyr)-Ser-Leu-OH 
• 768360-58-3 Boc-(3,5-dibromo-Tyr)-Ser-Leu-OH 
• 173383-15-8 C₆₇H₇₀Br₄N₈O₁₇ 
• 173383-14-7 C₆₇H₇₁Br₄IN₈O₁₇ 
• 173383-07-8 (S)-[(S)-2-[(R)-2-Amino-2-(4-benzyloxy-phenyl)-acetylamino]-3-(3,5-dibromo-4-hydroxy-phenyl)-propionylamino]-(3,5-dimethoxy-phenyl)-acetic acid methyl ester 
• 173383-11-4 (S)-{[(8R,11R,14S)-8-Amino-11-(4-benzyloxy-phenyl)-18,19-dibromo-4-hydroxy-5-iodo-9,12-dioxo-2-oxa-10,13-diaza-tricyclo[14.2.2.1^3,7]henicosa-1⁽¹⁹⁾,3⁽²¹⁾,4,6,16⁽²⁰⁾,17-hexaene-14-carbonyl]-amino}-(3,5-dimethoxy-phenyl)-acetic acid methyl ester 
• 173383-10-3 C₄₈H₄₇Br₂IN₄O₁₂ 
• 173383-09-0 (S)-[(S)-2-{(R)-2-(4-Benzyloxy-phenyl)-2-[(R)-2-tert-butoxycarbonylamino-2-(4-hydroxy-3,5-diiodo-phenyl)-acetylamino]-acetylamino}-3-(3,5-dibromo-4-hydroxy-phenyl)-propionylamino]-(3,5-dimethoxy-phenyl)-acetic acid methyl ester 
• 173383-16-9 C₆₀H₆₈N₈O₁₇ 

Relevant articles and documents

An efficient synthesis of l-3,4,5-trioxygenated phenylalanine compounds from l-tyrosine

A new strategy for the synthesis of l-3,4,5-trioxygenated phenylalanine derivatives from l-tyrosine is developed for the first time. The approach, featuring the transformation of aryl diiodide to bis-phenol via a one-pot procedure including lithiation, boronation, and oxidation, is highly practical. By this robust protocol, N-protected l-3,5-bis(tert-butyldimethylsilyloxy)-4- methoxy-phenylalanine and l-3,4,5-trimethoxy-phenylalanine derivatives were obtained from l-tyrosine in 9 steps with 36-40% overall yields.

The synthesis, distribution, and anti-hepatic cancer activity of YSL

(I) HCl/CH3OH; (II) DCC/HOBt/NMM with corresponding carboxyl component; (III) HCl/CH3CO2C2H5 (6 mol/L); (IV) NaOH/H2O/CH3OH; (V) 3H2 and 10% Pd/C. YSL was prepared stepwise from C terminal to N terminal with the side chain un-protective amino acids, Boc-Leu-OMe, Boc-Ser-OH, and Boc-Tyr-OH, as the starting materials in 39.5% total yield (31.2 g/per batch). With the side chain un-protective Boc-(3,5-dibromo)-Tyr-OH and HClA·Ser-Leu-OMe as the starting materials (3,5-3H-Tyr)-Ser-Leu-OH was obtained in 29% yield. The determination of radioactive quantity in the urine and feces indicated that even after the administration for 130 h only 8.4% (5.35% in urine and 3.05% in feces) of total radioactive quantity from the metabolite of [3,5-3H-Tyr]-Ser-Leu-OH were monitored. The distribution study revealed the relative accumulation level of the individual tissue was arranged in the sequence of spleen > liver > kidney > lung > heart > muscle > brain. Selecting hepatic cancer as the target YSL significantly increased the survival time of H22 tumor cells implanted mice.